BioCentury | Nov 12, 2015
Targets & Mechanisms

Breaking down beliefs

Researchers at the Genentech Inc. unit of Roche are challenging the widely held belief that the blood-brain barrier (BBB) breaks down in Alzheimer's disease to cause neurodegeneration and acts as a gateway for delivery of...
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...medications in rat and mouse models 2013 Targets and biomarkers for antiepileptogenesis (EPITARGET) Microvitae Technologies; to-BBB technologies B.V....
...London; University of Eastern Finland; University of Ferrara; University of Veterinary Medicine Neurology Unavailable Using to-BBB's...
...Institute; NIAID Infectious $31 million HIV/AIDS vaccine research consortium 2012 Drugs for Retinal Degeneration (DRUGSFORD) to-BBB...
BioCentury | Sep 29, 2014
Clinical News

2B3-201: Phase I data

...to include 18 additional healthy male volunteers, 6 healthy female volunteers and 18 MS patients. to-BBB technologies B.V....
BioCentury | Sep 15, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A. ; he succeeds interim CEO Leonard Kruimer, who remains CFO WIR...
BioCentury | Jul 14, 2014
Company News

to-BBB technologies B.V management update

to-BBB technologies B.V ., Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Pericles Calias as SVP of translational medicine, formerly senior director of nonclinical development of mRNA therapy at Shire plc Transitioned: CFO Leonard...
BioCentury | Jul 14, 2014
Financial News

to-BBB technologies B.V completes venture financing

to-BBB technologies B.V ., Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Date completed: 2014-06-30 Type: Venture financing Raised: EUR10 million ($13.7 million) Investors: New investors; existing investors WIR Staff...
BioCentury | Jul 14, 2014
Company News

Prosensa Holding N.V management update

...Hired: Willem van Weperen as chief commercial officer, a newly created position, formerly CEO of to-BBB technologies B.V. WIR...
BioCentury | Jul 1, 2014
Financial News

to-BBB raises EUR 10M in series C

...Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series...
...investors include Aescap Venture; Antea Participaties; Jonghoud International; and the Industrial Bank of Taiwan Management. to-BBB...
BioCentury | Jan 13, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Leonard Kruimer as CFO, formerly CFO of Crucell N.V. , which Johnson & Johnson acquired WIR Staff cancer Neurology...
BioCentury | Dec 23, 2013
Clinical News

2B3-201: Phase I started

...volunteers. Subjects will each receive an infusion of 2B3-201, placebo and methylprednisolone in 1-week intervals. to-BBB technologies B.V....
Items per page:
1 - 10 of 43
BioCentury | Nov 12, 2015
Targets & Mechanisms

Breaking down beliefs

Researchers at the Genentech Inc. unit of Roche are challenging the widely held belief that the blood-brain barrier (BBB) breaks down in Alzheimer's disease to cause neurodegeneration and acts as a gateway for delivery of...
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...medications in rat and mouse models 2013 Targets and biomarkers for antiepileptogenesis (EPITARGET) Microvitae Technologies; to-BBB technologies B.V....
...London; University of Eastern Finland; University of Ferrara; University of Veterinary Medicine Neurology Unavailable Using to-BBB's...
...Institute; NIAID Infectious $31 million HIV/AIDS vaccine research consortium 2012 Drugs for Retinal Degeneration (DRUGSFORD) to-BBB...
BioCentury | Sep 29, 2014
Clinical News

2B3-201: Phase I data

...to include 18 additional healthy male volunteers, 6 healthy female volunteers and 18 MS patients. to-BBB technologies B.V....
BioCentury | Sep 15, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A. ; he succeeds interim CEO Leonard Kruimer, who remains CFO WIR...
BioCentury | Jul 14, 2014
Company News

to-BBB technologies B.V management update

to-BBB technologies B.V ., Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Pericles Calias as SVP of translational medicine, formerly senior director of nonclinical development of mRNA therapy at Shire plc Transitioned: CFO Leonard...
BioCentury | Jul 14, 2014
Financial News

to-BBB technologies B.V completes venture financing

to-BBB technologies B.V ., Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Date completed: 2014-06-30 Type: Venture financing Raised: EUR10 million ($13.7 million) Investors: New investors; existing investors WIR Staff...
BioCentury | Jul 14, 2014
Company News

Prosensa Holding N.V management update

...Hired: Willem van Weperen as chief commercial officer, a newly created position, formerly CEO of to-BBB technologies B.V. WIR...
BioCentury | Jul 1, 2014
Financial News

to-BBB raises EUR 10M in series C

...Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series...
...investors include Aescap Venture; Antea Participaties; Jonghoud International; and the Industrial Bank of Taiwan Management. to-BBB...
BioCentury | Jan 13, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands Business: Drug delivery, Cancer, Neurology Hired: Leonard Kruimer as CFO, formerly CFO of Crucell N.V. , which Johnson & Johnson acquired WIR Staff cancer Neurology...
BioCentury | Dec 23, 2013
Clinical News

2B3-201: Phase I started

...volunteers. Subjects will each receive an infusion of 2B3-201, placebo and methylprednisolone in 1-week intervals. to-BBB technologies B.V....
Items per page:
1 - 10 of 43